The global oncology precision medicine market size is predicted to be worth USD 153.81 Billion in 2025. It can grow to a stellar valuation of USD 281.17 Billion by 2032. The market is anticipated to exhibit a CAGR of 9.0% during the forecast period (2025-2032). 

The sharp rise in cancer cases, advances in precision diagnostics, and personalized treatment plans are main drivers of the market. Investments in clinical trials and collaborations between diagnostic firms and pharmaceutical companies can support the strong growth.

However, the uneven access to precision medicine and surge in drug development processes due to kinase inhibitors can pose as hurdles to the market growth.

Key Market Insights

The oncology precision medicine market is expected to scale owing to leaps in CAR-T therapies, profiling of tumors, and integration of AI into workflows for enabling personalized treatment plans.

• By type of cancer, the breast cancer segment is predicted to capture a 13% share of the market in 2025. The integration of AI genomics and HER-2 targeted therapies can drive the growth of the segment. The molecular profiling of cancer patients can further shape the segment in the coming years.
• By route of administration, the intravenous segment is expected to attain 38% market share in 2025. This is on account of the use of targeted therapies and immunotherapies for delivering drugs to the bloodstream. The use of nanotechnology for the development of novel drugs and containers for agents can support the segment growth.
• By type of molecule, the biologics segment is anticipated to capture a significant market share over the forecast period. This can be attributed to the development of biologics for targeting the cGAS STING pathway for inhibiting the growth of tumor cells.
• By drug class, the kinase inhibitors segment is touted to display 10% CAGR over the forecast period owing to the targeting of specific signaling pathways that eliminate cancer cells. The inclination towards biomarker therapies can drive the segment growth.
• By region, Asia Pacific is touted to display a strong growth rate during the forecast period. This can be attributed to improvements in healthcare infrastructure in India and China, growing medical tourism, and collaborations between research firms and drug development companies.

The full report is now available for purchase: https://www.coherentmi.com/industry-reports/oncology-precision-medicine-market

Oncology Precision Medicine Market Report Coverage

Report Coverage	Details
Market Revenue in 2025	USD 153.81 Billion
Estimated Value by 2032	USD 281.17 Billion
Growth Rate	9.0%
Historical Data	2020–2024
Forecast Period	2025–2032
Forecast Units	Value (USD Billion)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered	By Type of Cancer, Route of Administration, Type of Molecule, and Drug Class
Geographies Covered	North America (U.S. and Canada), Latin America (Brazil, Argentina, Mexico, and Rest of Latin America), Europe (Italy, Spain, U.K., Germany, France, Russia, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific), The Middle East (GCC Countries, Israel, and Rest of Middle East), and Africa (South Africa, North Africa, and Central Africa)
Growth Drivers	Increasing Prevalence of Cancer Globally Growing Demand for Personalized Medicine in Oncology
Opportunities	Technological Advancements in Genomic Profiling Expanding Clinical Trials and Partnerships in Precision Oncology
Trends	IV-led Combination Therapies CAR-T Therapies
Restraints & Challenges	High Cost of Precision Medicines Regulatory Challenges in Approval Processes

Market Dynamics

The technological advances in bioinformatics, artificial intelligence, and genomics can drive the oncology precision medicine market growth. The use of AI-driven workflows and AI algorithms for the identification of mutations efficiently can bode well for the market. The utilization of CAR-T therapies for personalized treatments of cancers can drive the market growth. This is illustrated by the offerings by Johnson & Johnson, Gilead Sciences, Bristol-Myers Squibb, and Novartis.

Public-private partnerships and agreements between firms can also shape the global market in the forthcoming years. On July 07, 2025, Inocras Inc. and ChiMei Medical Center signed a memorandum of understanding to digitize the oncology landscape in Taiwan. The use of precision medicine to reduce the treatment cost of cancers and drive up the patient outcome levels can augur favorably for the market.

Market Opportunity: IV Precision Therapies to Bring About Transformational Outcomes

The use of intravenous precision therapies for targeting cancer development is likely to be a prime opportunity for players in the oncology precision medicine market. Alternatives to toxicity due to the use of chemotherapy can drive the trend in the coming years. According to a study in the Journal of the National Comprehensive Cancer Network on September 06, 2024, the use of a short intravenous bolus injection, 5-fluorouracil (5-FU), can reduce toxicity. It can be used in the treatment of advanced or metastatic gastrointestinal cancers.

Market Challenge: High Cost of Precision Medicines

The cost of molecular profiling and targeted therapies can raise the costs of precision medicines. The limited patient pool for the testing of novel drugs and expenses associated with the development of biomarkers can impede the market growth.

Analyst’s View

• The global oncology precision medicine market is driven by the rise of genomic sequencing for targeted therapies.
• The kinase inhibitors segment is expected to take the lead in the market in 2025 owing to their ability to target specific kinases and inhibit their growth.
• Key players are invested in agreements and collaborations to fund the treatment of novel and existing cancers.

Recent Developments

Ideaya Biosciences Inc. entered into a partnership with Gilead Sciences on February 13, 2025, to evaluate the efficacy of its molecule inhibitor in combination with the latter’s Trop-2 antibody-drug conjugate. The combined study can help evaluate the efficacy of the combination therapy on MTAP-deletion non-small cell lung cancer (NSCLC).

Competitor Insights

• Tempus
• Guardant Health
• Invitae
• Merck & Co.
• Caris Life Sciences
• Gilead Sciences
• Myriad Genetics
• Thermo Fisher Scientific
• Syapse
• Illumina
• Exact Sciences
• BioNTech
• Amgen
• Genomic Health
• Foundation Medicine

Market Segmentation

• By Type of Cancer
• Bladder Cancer
• Blood/Hematologic Cancer
• Breast Cancer
• Cervical Cancer
• Gastrointestinal Cancer
• Head and Neck Squamous Cell Cancer
• Lung Cancer
• Skin Cancer
• Others
• By Route of Administration
• Oral
• Intravenous
• Others
• By Type of Molecule
• Small Molecules
• Biologics
• By Drug Class
• Kinase Inhibitors
• Enzyme Inhibitors
• Immune Checkpoint Inhibitors
• Others

Regional Insights

• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Europe
  • Italy
  • Germany
  • U.K.
  • Spain
  • Russia
  • France
  • Rest of Europe
• Asia Pacific
  • South Korea
  • India
  • China
  • Japan
  • Australia
  • ASEAN
  • Rest of Asia Pacific
• The Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa